Therapeutic Asset Ratings

188 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
VEMURAFENIB laryngeal neoplasm	Cancer Research UK	P2/3	CCC (55)
VEMURAFENIB thyroid gland papillary carcinoma	Cancer Research UK	P2/3	CCC (55)
VEMURAFENIB thyroid gland undifferentiated (anaplastic) carcinoma	Cancer Research UK	P2/3	CCC (55)
Atezolizumab pancreatic neoplasm	Cancer Research UK	P2	CCC (54)
Cobimetinib non-small cell lung carcinoma	Cancer Research UK	P2/3	CCC (54)
Cobimetinib Solid Tumour	Cancer Research UK	P2/3	CCC (54)
Dabrafenib digestive system cancer	Cancer Research UK	P2/3	CCC (54)
Dabrafenib glioma	Cancer Research UK	P2/3	CCC (54)
Entrectinib cancer	Cancer Research UK	P2/3	CCC (54)
Entrectinib melanoma	Cancer Research UK	P2/3	CCC (54)
VEMURAFENIB glioma	Cancer Research UK	P2/3	CCC (54)
VEMURAFENIB Solid Tumour	Cancer Research UK	P2/3	CCC (54)
Atezolizumab kidney neoplasm	Cancer Research UK	P1/2	CCC (52)
Cobimetinib colorectal neoplasm	Cancer Research UK	P2/3	CCC (52)
Cobimetinib glioma	Cancer Research UK	P2/3	CCC (52)
Cobimetinib ovarian neoplasm	Cancer Research UK	P2/3	CCC (52)
Dabrafenib colorectal neoplasm	Cancer Research UK	P2/3	CCC (52)
Dabrafenib plasma cell myeloma	Cancer Research UK	P2/3	CCC (52)
Dabrafenib ovarian neoplasm	Cancer Research UK	P2/3	CCC (52)
Entrectinib glioma	Cancer Research UK	P2/3	CCC (52)
gsk1120212 ovarian neoplasm	Cancer Research UK	P2/3	CCC (52)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER colorectal neoplasm	Cancer Research UK	P2/3	CCC (52)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER ovarian neoplasm	Cancer Research UK	P2/3	CCC (52)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER pancreatic neoplasm	Cancer Research UK	P2/3	CCC (52)
Enzalutamide urinary bladder carcinoma	Cancer Research UK	P1/2	CCC (51)

Showing 76 to 100 of 188 assets

PreviousPage 4 of 8Next